BIOMAT Database Logo BIOMAT Database Logo

In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. 2021

Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
Antiinfectives Intelligence GmbH, Cologne, Germany; Rheinische Fachhochschule Cologne gGmbH, Cologne, Germany. Electronic address: michael.kresken@antiinfectives-intelligence.de.

UI MeSH Term Description Entries
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005858 Germany A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. The capital is Berlin.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078142 Tazobactam A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria. Tazobactam Sodium,YTR 830,YTR 830H,YTR-830,YTR830
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes

Related Publications

Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
The activity of ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa.
May 2021, Infectious diseases (London, England),
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
January 2015, Antimicrobial agents and chemotherapy,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
[In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
October 2019, Zhonghua wei zhong bing ji jiu yi xue,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa.
October 2025, The Journal of antimicrobial chemotherapy,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.
September 2021, Diagnostic microbiology and infectious disease,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
December 2017, Antimicrobial agents and chemotherapy,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
February 2021, Diagnostic microbiology and infectious disease,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
May 2016, Antimicrobial agents and chemotherapy,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales.
January 2023, Clinical laboratory,
Michael Kresken, and Miriam Korte-Berwanger, and Niels Pfennigwerth, and Sören G Gatermann, and
In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains.
June 2025, Infection,
Copied contents to your clipboard!